IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies.

ABSTRACT:

Purpose of review

Cell intrinsic and extrinsic perturbations to inflammatory signaling pathways are a hallmark of development and progression of hematologic malignancies. The interleukin 1 receptor-associated kinases (IRAKs) are a family of related signaling intermediates (IRAK1, IRAK2, IRAK3, IRAK4) that operate at the nexus of multiple inflammatory pathways implicated in the hematologic malignancies. In this review, we explicate the oncogenic role of these kinases and review recent therapeutic advances in the dawning era of IRAK-targeted therapy.

Recent findings

Emerging evidence places IRAK signaling at the confluence of adaptive resistance and oncogenesis in the hematologic malignancies and solid tissue tumors. Preclinical investigations nominate the IRAK kinases as targ

SUBMITTER: Bennett J 

PROVIDER: S-EPMC8654269 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature